Physician profile
Sara Farag
NPI 1831464932
$2,676.65
in general payments reported to CMS, 2019-2025
25 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $146 · 2021: $408 · 2022: $221 · 2023: $238 · 2024: $550 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.54 |
| Education | $203.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Applied Medical Resources Corporation | $716.36 | 2019-2020 | |
| Abbvie INC. | $462.97 | 2019-2025 | |
| Astellas Pharma US INC | $343.91 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $248.81 | 2021-2025 | Fluent Fluid Management System, Aptima, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $99.88 | 2021-2025 | |
| Millicent US INC | $87.17 | 2024-2025 | Intrarosa |
| Pfizer INC. | $83.94 | 2022-2024 | |
| Gynesonics, INC. | $68.17 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Evofem Biosciences, INC. | $67.53 | 2023-2025 | Phexxi, Solosec, Phexx |
| Merck Sharp & Dohme LLC | $52.81 | 2024-2025 | Gardasil, Gardasil 9, Zerbaxa |
| Avion Pharmaceuticals | $47.77 | 2019-2022 | |
| Agile Therapeutics, INC. | $40.45 | 2021 | |
| Janssen Scientific Affairs, LLC | $38.81 | 2024 | Balversa, Akeega |
| Teleflex LLC | $35.92 | 2019 | |
| Organon LLC | $31.12 | 2024-2025 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $30.88 | 2021 | |
| Genzyme Corporation | $30.50 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $29.87 | 2025 | |
| Scynexis, INC. | $28.30 | 2022 | |
| Myovant Sciences INC. | $26.17 | 2021 | |
| Coopersurgical, INC. | $24.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.15 | 2020 | |
| Mylan Pharmaceuticals INC. | $22.86 | 2021 | |
| Exeltis, USA INC. | $21.82 | 2024 | Slynd |
| Therapeuticsmd, INC. | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Farag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.